Key Takeaways
- Margin target hit early, growth stays priority: Nine-month EBITDA reached ~30% vs ~24% last year, achieving the 28-30% guidance ahead of schedule. Management will sustain this range to maximize growth, not margins further.
- Broad-based revenue momentum: CDMO grew ~31% YoY, CRO ~19% YoY, with large pharma engagement expansion driving both segments. Seven molecules added to late-phase and commercial pipeline during the year.
- Capacity build-out accelerating: Bidar expansion adds 450 KL by Q4 FY27 (~70% increase), plus a new Hyderabad site in 18-24 months with peptide and non-GMP capacity. Current utilization at ~60% provides headroom.
- Large pharma shift to India provides multi-year cover: CRO growth sustained despite weak biotech funding because large pharma pipeline coming to India offers enough cover for the next couple of years. No meaningful new biotech company formation expected for 18-24 months.
- What to watch next quarter: Pace of capacity commissioning at Unit 8 R&D and Bidar, utilization trends as new capacity comes online, and whether the remaining ₹18 crores provision reversal materializes.
Financial Performance
- Revenue mix stable: CDMO contributed ~65% of revenues, CRO ~35%. CDMO grew ~31% YoY, CRO ~19% YoY. Over 90% of CDMO revenues come from large pharma customers.
- Margin expansion drivers: Nine-month EBITDA at ~30% vs ~24% prior year, driven by operating leverage on employee costs of ~450 bps and material margin improvement of 100 bps from product mix and process efficiencies.
- Employee cost leverage to continue: As business grew, upfronted R&D-related people costs provided strong operating leverage. Expect this to continue into next year, though there could be periods of adding employees slightly ahead as they expand.
- Provision reversal: ₹16 crores reversed from the ₹34 crores provision taken last year March quarter. Remaining ₹18 crores reversal will happen as production on the commercial molecule progresses, not specifically in Q4.
- Consultancy charges: Double-digit consultancy charge in Q2 will not repeat. New AI enablement assignment will involve investment starting current quarter into next financial year.
- Revenue recognition: Based on completion, not dispatches. Some contracts allow revenue recognition on completion basis under Ind AS; others recognize on dispatch. Payment triggered by milestones or dispatch depending on contract.
Siva Chittor: "If you ask me, would you maximize margins or optimize your growth overall, I would probably optimize my growth where I maximize my growth potential and optimize my margins and to stay steady around the 28%, 30%, but grow faster that would then get us into a dominant larger position."
Capacity Expansion & Capex
- Bidar manufacturing: Intend to add 225 KL by June and another 225 KL by Q4 FY27, increasing manufacturing capacity by ~70%. Current utilization at ~60% provides adequate headroom for growth even ahead of new capacities.
- Unit 8 R&D expansion: First phase at recently acquired Hyderabad site scheduled to commission in Q4 FY26 with ~200 fume hoods for discovery chemistry.
- Process R&D building: Civil infrastructure on track, to be commissioned by September '26, doubling total process R&D capacity.
- Peptide facility: Process development and pilot facility targeted for September '26, expanding discovery and development peptide capabilities up to pilot scale.
- OEB laboratories: On schedule for October '26 completion, enhancing ADC capabilities for both discovery and clinical supply.
- Animal health Phase 1: Targeted for March '27 completion, enabling validation activities to commence API production for veterinary products. Unit originally built for another purpose, pivoted to animal health, focused on companion health space.
- New Hyderabad site: Expected up and running in next 18-24 months. Will include non-GMP capacity for faster early-stage development, significant peptide capacity based on pipeline forecast, and additional GMP capacity. Mixed-use facility providing more platform diversity.
- Technology-first approach: Not building capacity ahead of technology; want capacity to remain best in class five years down the road, not just capacity to win projects immediately.
- Capacity ramp-up visibility: Capacity coming online based on relative visibility from customer conversations and products in development (Phase 2 potentially going to Phase 3). Not real-time that plant is ready and product is ready to go.
Krishna Kanumuri: "We are taking a technology first approach to our capacity addition rather than just adding capacity for the sake of adding capacity. We want to ensure that our capacity remains best in class as you see five years down the road, as opposed to having capacity to win projects immediately."
Demand Environment & Competitive Positioning
- Large pharma shift to India: Global customers increasingly transitioning R&D FTEs and development activities to India, resulting in meaningful uptick in revenues and creating downstream opportunities for manufacturing portfolio.
- CRO resilience despite biotech weakness: Growth in CRO sustained because large pharma pipeline coming to India provides enough cover for the next couple of years. Business includes integrated programs (biology, DMPK) not just pure chemistry. Pharma component within CRO was negligible five years ago but has steadily increased.
- Biotech funding outlook: No meaningful new company formation in biotech expected to start for at least next 18-24 months. But enough growth from large pharma looking at India to cover next couple of years.
- Molecules shifting from China: A fairly large tranche moved around '23-'24 timeframe (significant portion of tech transfers in DRHP was supply source diversification). Beyond Biosecure Act, customers always look for multiple sources.
- Competitive moat from trust: Long history with large pharma customers creates barrier; most other CDMOs competing are relatively new in the space.
- Destocking risk management: The company has seen destocking years before. Lesson learned: keep portfolio as broad as possible, don't get excited only about $10M-$50M molecules, focus on $5M-$10M molecules. This allows quickly adding additional molecules to take care of ups and downs.
- Seven late-stage molecules added this year: At least a couple could have decent run from Sai revenue perspective based on industry sources.
Siva Chittor: "The only way that we can kind of protect ourselves or minimize impacts against destocking is to make sure that you have a slightly larger portfolio and we are not concentrated on one or two products that then can impact our revenue."
Margin Philosophy & Trade-offs
- Growth over margin maximization: Stated objective is to sustain 28%-30% margin while maximizing growth, not to maximize margins further. Internal targets are higher than street targets, but 28%-30% is the street-level guidance.
- Subscale risk vs China competition: Almost every CDMO/CRO player is subscale compared to China operating at 28%-30% margin. Over-optimizing for margin risks leaving market share and never being able to scale to compete long-term. India should focus on getting market share with reasonable return.
- Investment vs margin trade-off: There is always scope for margin improvement, but preference is to continue investing in technologies with long ramp-up times and higher quality people. The optimization is between growth and margin, not just cost improvement.
- Growth-related challenges from capex cycles: As the company enters larger capex cycles, there will be periods with utilization issues, upfront investments in people and technology that factor into operating costs. This is why 28%-30% is the sustainable range.
- Large pharma pricing dynamics: Growth in large pharma comes with open book/transparent pricing but gives larger volume and faster growth trajectory.
- Margin drop in '22-'23 context: Post '23 the company grew faster (possibly fastest in sector) because they had upfronted certain investments. The decision to invest in R&D, operating expenditure or capex is guided by longer-term factors and customer visibility, not one-year decisions.
Krishna Kanumuri: "If you over-optimize for margin, you potentially will be leaving market share never be able to scale and compete in the long term. So I think we have to be careful what we wish for."
New Modalities & Pipeline
- Peptide and ADC capacity: Reasonable visibility for both peptide expansion and ADC expansion, but timing is a quarter here quarter there when product comes.
- Oligo product: Under validation; commercial supply will start once validation is completed. Management declined to specify timing.
- New modality uncertainty: Very hard to predict which of the four modalities will be hottest 4 years down the road; only one or two might be hot, others might go on back burner.
- GLP-based products: Two products already launched; everything else is clinical pipeline. Management declined to comment on specific product pipeline or clinical stage breakdown.
- Animal health product validation: Intend to validate a product as phase one expansion completes (around 2027); filing time before product becomes commercial.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin | Sustain 28% to 30% range while maximizing growth | Ongoing |
| Revenue growth | Broad-based guidance of 15% to 20% | Not specific to a particular year |
| CDMO/CRO mix | Remain around 65-35% to 60-40% | Ongoing, with year-to-year variability |
| Employee cost leverage | Operating leverage on employee costs to continue | Into next year |
| Unit 8 R&D Phase 1 | Commission ~200 fume hoods for discovery chemistry | Q4 FY26 |
| Process R&D building | Commission, doubling total process R&D capacity | September '26 |
| Peptide process development facility | Expand discovery and development peptide capabilities up to pilot scale | September '26 |
| OEB laboratories | Complete, enhancing ADC capabilities | October '26 |
| Bidar capacity addition | Add 225 KL | June FY27 |
| Bidar capacity addition | Add another 225 KL, ~70% total increase | Q4 FY27 |
| Animal health Phase 1 | Complete, enabling validation activities for veterinary API production | March '27 |
| New Hyderabad site | Up and running with non-GMP, peptide, and GMP capacity | 18-24 months |
| Provision reversal | Remaining ₹18 crores to reverse as production progresses | Not specifically in Q4 FY26 |
| Biotech funding recovery | No meaningful new company formation expected | At least next 18-24 months |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue | ₹556 cr, +27% YoY vs ₹440 cr in Q3 FY25 |
| CDMO revenue share | ~65% of total revenue, grew ~31% YoY |
| CRO revenue share | ~35% of total revenue, grew ~19% YoY |
| EBITDA | ₹191 cr, +54% YoY, margin of 34% |
| Profit after tax | ₹100 cr, +86% YoY |
| 9M FY26 revenue | ₹1,590 cr, +43% YoY vs ₹1,115 cr in 9M FY25 |
| 9M FY26 EBITDA | ₹472 cr, +79% YoY, margin of ~30% vs ~24% in prior year |
| 9M FY26 PAT | ₹245 cr, +199% YoY |
| EBITDA margin guidance | 28% to 30%, achieved ahead of schedule, expected to be sustained |
| Capex invested in FY26 to date | ~₹405 cr |
| Capacity utilization | ~60% |
| Late-phase and commercial molecules added in 9M FY26 | 7 molecules, 3 commercial and 4 Phase III |
| Top customer concentration | ~12% of total revenue |
| Provision reversal in Q3 FY26 | ₹16 cr reversed, out of ₹34 cr provision taken in Q4 FY25 |